

Index

a

- ABC transporters 184
- $\alpha_4\beta_1$ integrin 296
- $\alpha_4\beta_7$ integrin 228
- ABO blood groups 286
 - antigens 301
- abscesses 6, 11, 16, 75, 161
 - structure 161
- $\alpha\beta$ T cell receptor (TCRs) 29, 30, 177, 210, 213
- acetylcholine receptors 266, 285
- acid proteases 59
- acquired immunodeficiency syndrome (AIDS) 2, 41, 50, 55, 56, 65, 72, 79, 88, 90, 93, 177, 178, 308
- acquired/secondary immunodeficiencies 55
- actin cytoskeleton 107, 149
- activated CD4 T cells 122, 284
- activated cytotoxic CD8 T cells (CTLs) 81
- activation-induced cytidine deaminase (AICD) 246, 248, 250, 252
- acute appendicitis 80
- acute inflammation 11, 12, 16–18, 21, 54, 70, 71, 75–77, 83, 103–106, 108, 109, 147, 149, 155, 232, 236, 266–268, 288–290, 291
 - bacteria causing 75
 - cardinal features 103
 - healing and repair in 108, 109
 - initiation of 104
 - leukocyte recruitment in 107
 - in skin 103
 - vascular changes in 105
 - viruses causing 84
- acute peritonitis 80
- acute-phase response 107, 108, 144, 155, 167, 168
 - acute phase reactants 93
- adaptive immune responses 227
- adaptive immune system 228, 294, 310, 312
- adaptive immunity 5–9, 19, 23, 27, 34, 38, 55, 65, 109, 111–113, 168, 227, 228, 259
 - adaptive responses 11
 - anatomical organization 112
 - antigen receptors 310
 - cells, directly link 14
 - cytokines in 34, 35
 - features 250
 - functional anatomy of 111–126
 - initiation of 109
 - mechanisms of 65–69
 - self–non-self discrimination 37
 - tissue monitoring in 113
 - types of recognition in 8
- adaptor molecules 38, 138
- ADCC. *See* antibody-dependent cell-mediated cytotoxicity
- adenoids 11, 111
- adhesion molecules 24, 25, 103, 105, 144, 194, 228
- adipose tissue 108
- adjuvants 44, 45, 95, 138, 141, 171–174, 172, 173
- adoptive transfer 57, 58, 85, 119, 122, 178, 244, 250, 294
 - of immunity, principle 58
- adrenaline 265, 280, 283
- afferent lymph 10, 23, 117, 118, 120, 121, 168, 196
- afferent lymphatics 113, 114
- African sleeping sickness 53
- α -galactosylceramide (α -GalCer) 190
- agonists 8
- AICD 248, 249, 252
- AIRE 211, 212, 215
- airways 6
- Akt pathway 195
- alarm 7, 15, 105
 - cells 9, 104, 106, 112, 149, 151, 154
 - molecules 142
 - signals 63, 134
- alcohol 110, 111
- alleles 33, 179
 - allelic exclusion 210, 224, 252
 - allelic variants 128
- allergies 41, 42, 43, 260, 263, 264, 278, 279
 - allergens 263, 274, 279, 280, 282
 - diseases (type I hypersensitivity reactions) 279
 - disorders 69
 - mechanisms 279
 - peanut 280
 - peanut anaphylaxis 281
 - pollen 283
 - reactions 17, 263
 - responses 17, 18, 72, 229
 - rhinitis 279
 - susceptibility to 281
 - treatment 283
- allogeneic 43, 300, 301
 - allogeneic grafts 302
 - allograft rejection 216, 302, 303
 - acute 43, 302–305
 - chronic rejection 43, 305
 - effector mechanisms 304
 - hyperacute rejection 43, 301
 - allografts 43, 178, 274, 276, 293, 300–303, 306
 - alloreactivity 43, 44, 271, 300, 307
 - alternative activation 16, 203
 - alum 96, 172, 281
 - adjuvanticity, possible mechanisms 172
 - alveoli of lungs 154
 - amino acid sequencing 220
 - amoebic dysentery 53
 - anaerobic 74, 75
 - anaphylactic shock 279
 - anaphylatoxins 155, 236
 - anaphylaxis 42, 229, 264–266, 279–281, 283, 286
 - anatomical basis, of immunity 9
 - anchor residues 181
 - anergy 31, 38, 39, 192, 198, 253, 254, 255, 283
 - angiogenesis 89, 145, 149, 162
 - angiogenic effects 34
 - animal models 281, 289
 - of diabetes 292
 - animal studies 278, 294
 - ankylosing spondylitis 277, 299
 - annexin V 151, 153
 - anoxia 302
 - anterior kidney 130
 - antibody–antigen complexes 155, 156
 - antibody avidity 226
 - antibody-based therapies 261. *See also* therapeutic antibodies
 - antibody classes (isotypes) and properties 224–229
 - common mucosal immune system 229
 - IgA 227–229
 - IgD 226–227
 - IgE 229
 - IgG 227
 - IgM 224–226
 - mucosal immunity 228, 229
 - natural antibodies 226
 - antibody-dependent cell-mediated cytotoxicity (ADCC) 65, 71, 164, 165, 229, 234, 236, 248, 265, 266

- antibody(ies) 6–10, 14, 34–37, 42, 60, 61, 69, 73, 75, 81, 82, 85, 87, 93, 106, 112, 121, 139, 201, 217, 263, 265, 268, 295, 297, 304, 309.
See also monoclonal antibodies; therapeutic antibodies
 - acute inflammation, induction 236
 - affinity 226
 - and avidity 225, 226
 - maturation 30, 123, 241, 245, 248, 249
 - maturation *in situ* 249
 - biological properties 224
 - classes of 225
 - class switching 30, 123, 237
 - isotype switching 124
 - defence against infection 231–236
 - dependent modulation of function 265
 - diversity 220, 224
 - in other species, generation 224
 - engineering 254, 255
 - and Fc receptors 35
 - forming cells 217
 - functions 35, 37
 - in defence 231
 - genes 220
 - heavy (H) chains 28, 218, 220
 - and light (L) chains 28
 - hypervariable regions 47, 209, 218, 220
 - mediated resistance, to re-infection 250
 - multi-molecular complexes of 266
 - preformed 301, 302
 - recognizing antigens 218
 - responses primary and secondary 243
 - roles 254
 - structure/function 218–236
 - allelic and isotype exclusion 224
 - antibody diversity, generation 220–224
 - immunoglobulin genes DNA, rearrangement 220–224
 - immunoglobulins and antibodies 218
 - synthesis 217, 251
 - tissue distribution 227
 - toxin, and pathogen neutralization by 234
 - antibody-secreting (B) cells 45
 - anti-cytokine antibodies 294
 - antigen–antibody complexes 242, 267, 288
 - antigen–antibody interactions 225
 - antigen-based therapies 261
 - antigen-based vaccines 261, 262
 - antigen-binding groove 32
 - antigen-binding sites 220
 - antigen–C3d complex 242
 - antigenic variation 91, 93, 215
 - antigen-presenting cells (APCs) 32, 182, 235, 244
 - professional 182
 - antigen processing 177, 182, 185
 - subversion 188
 - antigen receptor genes
 - formation, junctional diversity 211
 - rearrangement of 28
 - antigen receptors 8, 24–26, 259, 270
 - antigen recognition 111, 121, 270
 - by B cells 121–123
 - antigens 8, 126, 218
 - cellular basis 182
 - classical MHC molecules 179–182
 - cross-presentation 187, 188
 - detection 233
 - dose 200
 - drift 86
 - internalization 29
 - isolation 233
 - lipid antigens by CD1 molecules 188–191
 - MHC class II presentation 185–187
 - MHC class I presentation 182–185
 - non-classical MHC molecules 182
 - pathogens, subversion 188
 - presentation 23, 123, 179, 182
 - recognition by CD4 and CD8 T cells 33
 - repertoire 270
 - storage 207
 - topography 221
 - transport 119
 - uptake and processing 23
 - antigen-specific therapy 299
 - antihistamines 265
 - anti-HPV virus vaccine 89
 - anti-inflammatory cytokines 34, 145
 - anti-inflammatory drugs 291, 297
 - anti-microbial peptides 142, 148
 - anti-microbial toxins 58
 - anti-receptor antibodies 285
 - anti-Rh antibodies 235, 287, 288
 - anti-self receptors 253
 - anti-TNF- α therapy 298
 - anti-TNF- α antibodies 254, 256
 - anti-TNF- α monoclonal antibody 144, 297
 - anti-tumour T cells 309
 - anti-viral resistance 143
 - AP-1 138, 140, 194, 195
 - APECED. See autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED)
 - apoptosis 15, 18, 19, 21, 63, 68, 79, 90, 92, 129, 150, 151, 153, 192, 203, 204, 210–212, 214, 238, 289
 - apoptotic cells 134, 153, 155, 290
 - assessment of 153
 - apoptosome 206
 - appendix 111, 127
 - arachidonic acid 147, 148
 - Artemis 211, 223
 - arteries 10
 - arterioles 10, 105
 - asbestos 141
 - Aspergillus* 91, 92
 - assassin bugs 53
 - asthma 65, 276, 277, 280–283
 - animal models of allergy 281, 282
 - immune-mediated asthma 282
 - pathogenesis 280, 281
 - people becoming allergic 281
 - treatment of allergy 283
 - atherosclerosis 136
 - athlete's foot 53
 - atopy 281
 - ATP 275
 - attenuated organisms 45, 96
 - attenuation 84, 96
 - autoantibodies 38, 41, 294
 - autocrine 33, 34, 198, 199
 - autograft 300, 301
 - autoimmune diseases 2, 19, 38, 41–43, 47, 109, 130, 195, 213, 216, 226, 254, 260, 276, 278, 291, 306
 - autoimmune disorders 66
 - autoimmune responses 273
 - autoimmunity 66, 211
 - autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED) 211, 259, 260
 - autoinflammatory diseases 141, 261
 - autophagy 289, 296
 - autoradiography 116
 - autoreactive receptors 38
 - avidity 69, 225, 226
 - axon reflex 105
- b**
- B7 31, 192, 194
 - B-1a cells 226, 241
 - bacilli 53
 - Bacillus Calmette–Guérin (BCG) 77, 95, 178
 - bacteria 173
 - bacteria 6, 14, 50, 52, 54, 160, 169, 208
 - capsules 75
 - exotoxins 231
 - food poisoning 80
 - bacterial infections, pathogenesis of 53, 72
 - acute inflammation 75, 76
 - chronic inflammation 76–79
 - intestinal inflammation 79, 80
 - malignant tumours 80
 - septic shock 80
 - toxins secretion 72, 73
 - bacterial type III secretory systems 79
 - bacteriophages 169, 256
 - BAFF 252
 - BALB/c mice 200, 201, 204
 - bare lymphocyte syndrome 190
 - barriers 21, 51, 72, 81, 101, 201, 306
 - basement membrane 10
 - basophils 14, 17, 18, 23, 64, 67, 68, 118, 147, 200, 203, 227, 233
 - B-1 B cells 218, 219, 253
 - B-1 cells 21, 22, 226, 252
 - B-2 B cells 253
 - B-2 cells 218, 252
 - differentiation of 252
 - 4-1BB/L 202
 - B cell activation 124, 241, 243
 - B cell deficiency 252
 - B cell differentiation, and selection 252–254
 - B cell populations, development 217, 252
 - B-2 cells 252, 253
 - B cell tolerance 253, 254
 - B cell epitopes 29, 271
 - B cell follicles 91, 191
 - B cell hybridomas 249
 - B cell memory 250, 251
 - B cell populations 217, 219
 - development of 252
 - B cell receptors (BCRs) 7, 9, 27–29, 38, 218, 242, 243, 269, 270, 271, 277
 - functions of 28, 29
 - B cell responses 121, 236–250
 - activation, intracellular signalling pathways in 242
 - activation, positive and negative regulation 243
 - anatomical basis 237–239
 - BCR signalling 241, 242

- differentiation 253
 - epitopes 272
 - fates of activated B cells 238, 239
 - germinal centre reaction 237, 238
 - interactions between T and B cells during 237
 - memory 251
 - populations 217–219
 - TD antibody responses, functional anatomy 237–239
 - TI antibody responses 239–243
 - TI-2 antibody responses, functional anatomy 237
 - tolerance in bone marrow 254
 - tolerance mechanisms 255
 - tumours 220
 - types 217
 - B cells 3, 7, 8, 11, 12, 14, 21, 22, 69, 114, 117, 119, 123, 127, 129, 175, 207
 - activated cells 155, 238, 240, 245
 - fates of 240
 - activation, physiology 217
 - antigen receptors, functions 29
 - naïve B cells 217, 224
 - negative regulation of B cell activation 242
 - positive regulation of B cell activation 242
 - pre-B cell 252
 - pre-BCR 252
 - pro-B cell 252, 253
 - role in adaptive immunity 217
 - self-reactive follicular B cells 253
 - tolerance 253, 254
 - types of 22
 - β cells 292, 293
 - BCG 95
 - Bcl-2 90
 - Bcl-6 199, 237, 247
 - BCRA-1 309
 - BCRA-2 309
 - BCRs *See* B cell Receptors
 - BCR signalling 241
 - Bence-Jones proteins 220, 221
 - benign tumours 44, 306, 307
 - beta chains 29, 32
 - B7H1 195
 - bile 101
 - biotin 207
 - birds 130
 - bladder 101
 - BLNK 241
 - blocking pathogen binding 231
 - blood 10, 11
 - blood and lymphatic vessels (angiogenesis) 109
 - blood-borne antigens 125, 226
 - blood-borne immune complexes 266
 - blood cells, development of 126
 - blood coagulation 104, 154, 163
 - blood group antibodies 286
 - and disease 286
 - blood group antigens 302
 - blood platelets 104
 - blood, role in immune system 10
 - blood transfusion 87, 261, 286
 - blood vessels 10
 - B lymphoblasts 123, 124
 - B lymphocytes 20, 21, 69, 217. *See also* B cells
 - β2-microglobulin 32
 - B7 molecules 31
 - bone marrow 11, 12, 34, 38, 107, 108, 121, 123, 124, 126, 127, 168, 240, 252–254, 307
 - transplantation 43, 130, 300, 306
 - botulism 73
 - bovine spongiformencephalopathy (BSE) 50
 - bradykinin 154
 - permeability 154
 - brain 108
 - breast milk 69, 125, 229
 - broncho-constriction 265, 280–282
 - bronchus-associated lymphoid tissues (BALTs) 111
 - Bruton's tyrosine kinase (Btk) 241
 - Bruton's X-linked agammaglobulinaemia 252
 - Btk 252
 - budding 52
 - Burkitt's lymphoma 88
 - Bursa of Fabricius 127, 130, 224, 316
 - butterfly rash 267, 289
- c**
- cachexia 144, 167
 - calcineurin 194, 196, 304
 - calcium 194
 - Campath-1 (alemtuzumab) 296
 - Campylobacter jejuni* 283, 284
 - cancers 44, 55, 107, 198, 260
 - problem 2
 - Candida albicans* 6, 91, 92
 - capillaries 10
 - capsular polysaccharide 75, 77, 241
 - capsules 60, 69, 126, 159
 - carbohydrate antigens 218
 - carbohydrate capsules 96
 - carbohydrates 7, 21, 240, 241
 - carcinoma 306
 - cardiovascular shock 80, 144
 - carriers 55, 96, 225, 244
 - cartilaginous fishes 224
 - cascade 35, 36, 155, 156
 - caspase 206
 - caspase-1 141
 - catalase 159
 - cathelicidins 146, 148, 160
 - gene 146
 - cathepsin 160
 - C57BL/6 mice 201, 204
 - CCR5 90, 92
 - CCR7 208
 - CD3 30, 31, 192–195
 - CD4 52, 193, 296
 - CD8 193
 - CD14 136, 281
 - CD16 163, 165
 - CD19 31, 242, 243
 - CD21 242
 - CD22 242
 - CD25 68, 121, 199, 298
 - CD27 244
 - CD28 31, 192, 194, 195
 - CD31 154
 - CD36 134, 150
 - CD40 195, 201, 202, 214, 242, 246
 - CD43 194
 - CD45 128, 194
 - CD46 157
 - CD52 296
 - CD55 157
 - CD59 157
 - CD69 121
 - CD70 244
 - CD79 28, 29, 31, 241–243
 - CD80 192, 194
 - CD80, 86 31
 - CD81 242, 243
 - CD86 192, 194
 - CD5 B cells 218
 - CD5 B-1 cells 226
 - CD11c 196
 - Cdc42 149
 - CD70/CD27 203
 - CD19–CD21–CD81 complex 242
 - CD40–CD40 ligand 248
 - CD40 ligand 31, 32, 201, 202, 246
 - gene 246
 - CD1 molecules 182, 188, 189, 210
 - lipid antigens presentation 189, 190
 - CDR1 220
 - CDR2 220
 - CDR3 220
 - CD4 T cells 14, 19, 20, 22, 24, 29, 30, 32, 43, 50, 64, 65, 77, 82, 84, 90, 92, 117, 119, 121, 123, 194, 198, 213, 217, 245, 263, 292, 293, 295, 302, 304
 - activated, migration of 122
 - activation 267, 274
 - antigen recognition by 33
 - costimulation 192
 - effector functions of 198–202
 - non-steady state 198
 - polarization 276
 - responses 227
 - transcription factor 282
 - CD8 T cells (CTLs) 14, 19–21, 30, 32, 66, 68, 69, 78, 81, 82, 84–86, 93, 117, 122, 182, 202, 206, 215, 263, 269, 295
 - antigen recognition by 33
 - cytotoxic T cells 14, 19, 21, 42, 90, 151, 268, 292
 - cytotoxic T lymphocytes (CTLs) 14, 18, 20, 33, 203
 - effector functions of 202–205
 - functions 68
 - cell-associated, and soluble molecules of immunity 24
 - cell-associated PRRs 27, 134
 - cell-associated recognition systems, in immune system 26
 - cell-based therapies 262
 - cell fractionation 188
 - cell-mediated immunity 12, 13, 14, 201, 286
 - cell-mediated (type IV) hypersensitivity reactions 291
 - cell-mediated immune responses 267
 - mechanisms of 14
 - cell-positioning molecules 25
 - cell signalling 36
 - components 36, 37
 - cell sorting 122
 - cellular cytotoxicity 18, 19, 24, 63, 64
 - mechanisms of 19
 - cellular distribution of PRRs 142
 - cellular effectors, recruitment of 106
 - cellular methods 305

- central arteriole 126
 central nervous system (CNS) 76, 81, 83, 168, 182, 294, 295
 cerceriae 55
 cervical carcinoma 88, 89, 309
 Chagas' disease 53
 cheetahs 180
 chemoattractant 155, 236
 chemoattractant cytokines 35
 chemokine receptors 25, 26, 35, 199, 253
 chemokines 24–26, 34, 35, 106, 118, 148, 149, 154, 158, 159, 164
 chemotactic factors 106
 chemotaxis 25, 35, 106, 158
 chemotherapeutic drugs 161
 chemotherapy 91, 309
 chickenpox 52, 95
 chickens cell 52, 127, 224
 chloride ions (Cl⁻) 160
 chloroquine 186
 cholera 53, 73, 74, 97, 231, 234
 – pathogenesis of 76
 – toxin 72, 173
 chromatin 61
 chromosomes 217
 chronic granulomatous disease (CGD) 56, 130, 162
 chronic infections 45, 87, 216
 chronic inflammation 11, 12, 54, 62, 76–78, 86–88, 103, 106–108, 110, 144, 280, 282, 285, 292, 294, 296–299
 – bacteria causing 76–79
 – conditions 130
 – repair in 110
 – viruses causing 86–87
 cilia 101, 102
 cirrhosis 87, 88, 110, 111
 citrullinated polypeptides 297
 c-Kit ligand 170
 classical DCs 22, 23, 86, 101, 102, 114, 118, 196
 class II transactivator (CIIT) 190
 clinical and subclinical infection 56
 CLIP 186, 187
 clonal deletion 38, 39, 253
 clonal expansion 12, 120, 199
 clonotypic antibodies 193
Clostridium tetani 53, 75
 See common lymphoid progenitors
 CMP 13, 128
 CMPs 171
 coagulase 161
 cobra venom factor 238
 cocci 53
 coeliac disease 277, 294
 cold chain 95
 collagen 10, 87, 88, 109–111, 161
 collagenase 62, 109, 150, 162
 collateral damage 40, 70, 76, 78, 214, 260, 267
 – tissue damage 275
 collectins 153, 155
 colonoscopy 297
 colony forming units of the spleen (CFU-S) 128
 colony-stimulating factor (CSF) 128
 colostrum 44, 95
 commensal bacteria 37, 53, 59, 99, 102, 224, 241, 297
 – commensal intestinal bacteria 278, 293
 – commensal intestinal flora 102, 296
 commensalism 53
 common cold 81, 83
 common dendritic cell precursor 128
 common lymphoid progenitors (CLPs) 12, 13, 127, 128, 196, 252
 – common lymphocyte precursor 270
 – common lymphoid precursors 21, 127, 163, 164, 253
 common mucosal immune system 125, 229, 230
 common myeloid progenitors (CMPs) 12, 127, 196
 complement 6, 9, 11, 12, 17, 28, 31, 35, 36, 39, 42, 60, 69–71, 77, 91, 106, 118, 154, 155, 162, 163, 225, 226, 231, 233, 238, 242, 266, 268, 288, 290, 291, 301, 302
 – activation 36, 37, 61, 156, 232
 – and production of opsonins 61
 – activation and functions 155, 156
 – alternative pathway activation 35, 36, 156, 157
 – classical pathway activation 156
 – regulation of complement activation 157
 – and antibodies, shared functions 35
 – C2 157
 – C3 36, 61, 154–157, 238
 – C3a 65, 149, 155, 233
 – C3b 61, 75, 77, 155, 156
 – C3bBb 156
 – C4 157
 – C4a 155
 – C4b2a 156
 – C5a 65, 149, 155, 158, 159, 233
 – C9 complement 203
 – C3 convertases 155–157
 – C3d 242, 243
 – C4 deficiency 289
 – C9 deficiency 157
 – central complement defects 157
 – classical pathway 35, 36, 61
 – activation 156
 – complement deficiencies 157
 – complement-derived peptides 149
 – complement-mediated lysis 265, 286
 – C1q 61, 156, 157
 – C1q complement component 226
 – C1q deficiency 289
 – C1r and C1s 156
 – CR1 receptors 155
 – deficiencies 56, 157
 – direct pathway 302, 303
 – early complement component defects 157
 – functions 35, 36
 – iC3b 61, 75, 77, 155, 157
 – late complement defects 157
 – lectin pathway 36, 61, 156
 – activation 155
 – pore formation 36
 – and receptors 35
 – subversion of complement activation 157
 complementarity-determining regions (CDRs) 176, 177, 220
 – types 220
 complement C4 289
 complement C5 298
 complement fragments C3a and C5a 236
 complement receptors 35, 60, 155, 241, 242, 251, 266
 complement receptor type 2 (CD21) 243
 complement regulators 155
 concanavalin A (Con A) 130
 concentration gradient 25, 159
 concomitant immunity 309
 concordance 277, 281, 294, 296, 297, 299
 – rates 294
 – in twin studies 277
 conduits 114, 115, 117–119, 121
 conformational epitopes 27, 218, 271
 conjugate vaccines 76, 96, 97, 241
 connective tissue 109
 constant (C) regions 220
 – types 220
 contact sensitivities 43, 214, 265
 coordination of immune responses 23
 coreceptors on T cells 30
 – functions of 30
 cortex 114
 corticosteroids 283, 289, 291, 299, 305
 costimulation 22, 23, 31, 191, 192, 194, 199, 241
 – costimulatory molecules 23, 31, 39, 194, 272, 311
 – costimulatory signals 117
 – generation 272
 – of lymphocytes 31
 – PAMPs inducing 274
 cowpox virus 44, 96
 cows 208
 Coxsackie virus 292, 293
 CpG 96, 135, 137, 173, 239
 C regions 220
 C (constant) region segments 28
 Crohn's disease 267, 276, 277, 292, 296, 297
 – animal studies 297
 – pathogenesis 296, 297
 cross-presentation 187, 189
 cross-reactivity 271, 272
Cryptococcus 91, 92
 crystallography 137
 CTLA-4 192, 195, 278
 CTLA-4 gene knock-out mice 195
 C-type lectin receptors 27, 134
 curarisation 75
 CXCR4 90
 CXCR5 208
 cyclic AMP 74
 cyclo-oxygenases 148
 cyclosporin 195, 304
 cysteine protease 280
 cystic fibrosis 101
 cystitis 50, 53, 101
 cytokeratin 3
 cytokines 15–18, 21, 22, 24, 25, 27, 33, 34, 62, 63, 65, 80, 109, 118, 136, 137, 148, 164, 166, 168, 171, 199, 200, 205, 241, 279
 – in adaptive immunity 34, 35
 – analysis 144, 145, 146
 – in innate immunity 34, 143
 – in myelopoiesis 171
 – production 144
 – receptors 25, 33, 38
 – secretion 146, 147, 205
 – storm 196
 – synthesis 244

- therapy 262
 - cytomegalovirus (CMV) 178, 296
 - human CMV 166, 188
 - infection 165
 - cytoplasmic granules 16–18
 - cytoplasmic PRRs 27
 - cytotoxic CD8 T cells 264, 294
 - cytotoxic cells 9, 21
 - cytotoxic hypersensitivity reactions 263, 283
 - cytotoxicity 203–205
 - cytotoxic type II hypersensitivity 266
- d**
- danger 7, 8, 133
 - hypothesis 134
 - danger (or damage)-associated molecular patterns (DAMPs) 104, 134, 137, 172, 274–276
 - dark zone 123, 239
 - Darwin 308
 - Darwinian selection 44, 45
 - DCs. *See* dendritic cells
 - death-inducing receptors 63, 64
 - decay accelerating factor (DAF) 157
 - dectin-1 134
 - dectin-2 134
 - defective ribosomal products (DRIPs) 181
 - defence against infections 231–236
 - acute inflammation, induction of 232–234
 - adaptive immunity, modulation 235
 - antibody-dependent cellular cytotoxicity (ADCC) 234
 - blocking pathogen binding 231, 232
 - mast cells, basophils and eosinophils, sensitization of 233, 234
 - mechanisms 6
 - pathogen opsonization 232
 - toxin neutralization 231
 - defensins 35, 62, 100, 102, 107, 146, 148, 160
 - degranulation 17, 65
 - delayed-type hypersensitivity (DTH) 43, 178, 214, 263, 265
 - responses 43, 119
 - dendritic cells (DCs) 9, 12, 14, 20–24, 31, 39, 52, 62, 68, 84, 92, 101, 112, 114–121, 123, 125, 127, 128, 142, 147, 168, 172, 176, 187, 189, 191, 192, 194, 196, 197, 200, 202, 211, 212, 214, 216, 228, 238, 243, 247, 262, 272, 274, 275, 302, 303, 305, 309
 - classical 196
 - classical, functions of 23
 - Langerhans cells 197
 - MHC class I molecules 189
 - migratory DCs 23
 - monocytes 197
 - peripheral self-tolerance 214
 - plasmacytoid 198
 - populations 197
 - resident 23, 117, 118
 - T cell activation and polarization 196–198
 - T cell responses, initiation 196
 - TNF- and iNOS-producing (TIP) 198
 - viral tropism 187
 - dendritic epidermal T cells 213
 - dengue fever 97, 232
 - dermis 101
 - Der P1 280
 - Der P2 280
 - desensitization 261, 283
 - Dhobie itch 53
 - diabetes 292, 293
 - diacylglycerol (DAG) 194, 195
 - diarrhoeal disease 53, 69, 73, 74, 79, 229
 - DiGeorge syndrome 129, 178
 - dimeric IgA 71
 - dinitrophenol (DNP) 218
 - diphtheria 73, 231
 - diphtheria toxin (DTX) 196
 - direct cell death
 - pathogenesis 81–83
 - viruses causing 81–84
 - direct killing 14
 - diseases 107, 266. *See also* immunopathology
 - caused by antibody-dependent modulation of function 265, 266
 - caused by blood-borne immune complexes 266, 267
 - caused by cell-mediated immune responses 267, 268
 - caused by IgE antibodies 263–265
 - caused by immune complexes 288
 - caused by local deposition of immune complexes 267
 - concordance in twins 277
 - immunopathological mechanisms, classification 263
 - and immunotherapy 261, 262
 - initiation and effector phases 262, 263
 - markers 294
 - mediated by immune complexes 266, 267
 - diversity, generation 210
 - DNA 256, 290
 - encoding V regions 237
 - sequences 245
 - DNA methylation 277
 - DNA rearrangement 8, 28, 30, 220, 221
 - DNA vaccines 96, 173
 - dogs 305
 - dormancy 78, 79
 - double-stranded RNA 137
 - drinking water 53
 - droplets 53, 83
 - drug-induced haemolytic anaemia 287
 - drug sensitivities 43, 285
 - DTX receptor 196
 - dye dilution 121
 - dysentery 53
- e**
- early proteins 52, 85
 - Ebola fever 59
 - eclipse phase 85, 92
 - eczema 100, 280
 - effector cells and molecules 9
 - effector mechanisms 5, 42, 304
 - effector molecules 24, 35, 106
 - of immunity 35
 - responses 22
 - efferent lymph 10, 116, 117, 119
 - efferent lymphatic(s) 114
 - eicosanoids 147
 - elastase 62, 109, 150, 162
 - elastin 110
 - electron microscopy 188
 - electrophoresis 139, 140, 151, 188
 - elimination phase 310
 - ELISPOT assays 233
 - embryonic (ES) stem cells 57, 127, 130
 - encephalitis 140
 - endocrine 33, 34
 - endocytic receptors 25, 137
 - endocytosis 15, 52, 59
 - mechanisms of 15
 - receptor-mediated endocytosis 15, 59, 134
 - endogenous antigens 33, 183
 - endogenous pyrogen 141
 - endolysosomes 59
 - endosomal PRRs 27
 - endosomes 15, 32, 52, 59, 135, 136, 160, 186
 - degradation 185
 - endothelial cells 10, 15, 27, 103, 105, 142, 150–152, 154, 226
 - regulation of leukocyte recruitment by 152
 - endothelium 25, 103, 105, 106
 - endotoxic shock 80, 136
 - endotoxins 72, 80, 134, 309
 - Entamoeba histolytica* 53
 - enterocolitis 103
 - envelope 50, 83
 - enzyme-linked immunosorbent assay (ELISA) 144, 233
 - eosinophilic gastroenteritis 276
 - eosinophils 14, 17, 18, 21, 23, 64–67, 102, 118, 229, 233, 234, 236, 280
 - properties and functions 65
 - eotaxin 65
 - epidemics 85, 86
 - epidermis 101
 - epigenetics 277
 - epigonal organs 130
 - epithelia 6, 10, 51, 104
 - epithelial cells 83, 109, 110, 142, 145–147
 - epitopes 271
 - epitope spreading 274, 276, 285, 294
 - Epstein–Barr virus (EBV) 88, 283, 284, 308
 - equilibrium dialysis 225
 - equilibrium phase 310
 - ER-resident aminopeptidase-1 (ERAP1) 184
 - erythrocytes (RBCs) 10, 12, 155
 - erythropoietin 12
 - escape mutants 91, 93
 - Escherichia coli* 50, 53, 146
 - eukaryotes 50
 - evasion mechanisms 90
 - exogenous antigens 33, 186
 - exogenous peptides 187
 - exotoxins 72, 196, 231, 234
 - experimental autoimmune encephalomyelitis (EAE) 294. *See also* multiple sclerosis
 - extracellular bacteria 12, 53, 61, 63, 66, 75, 202
 - extracellular pyogenic bacteria 232
 - extravasation 24
 - extravascular fluid 10
 - extrinsic antigens 260
 - exudation 105
 - eye 11, 100
- f**
- Fab 220, 222, 226
 - F(ab')₂ 220, 222, 226
 - Factor B 156
 - Factor H 157

- Factor I 157
 Factor XII (Hageman factor) 154
 facultative intracellular parasites 53, 163
 Farmer's lung 43, 288, 289, 291
 Fas 18, 35, 68, 90, 195, 204, 206, 272
 Fas ligand 18, 19, 35, 68, 90, 195, 204, 272
 Fas ligand-Fas interactions 21
 Fc 60, 220
 Fc γ RIII 163
 Fc α PI 248
 Fc γ RI 248
 Fc γ RIIB 242, 243
 Fc γ RIIB1 248
 Fc receptors (FcRs) 35–37, 60, 66, 149, 150, 152, 163, 201, 225, 226, 229, 231, 233, 235, 236, 242, 248, 251, 264
 – high-affinity IgE Fc receptors (FcRs) 263
 Fc region 222
 FcR for IgE 281
 FDCs. *See* follicular dendritic cells
 fever 75, 82, 84, 92, 108, 141, 144, 166, 168
 fibrin 109, 161
 fibrinogen 137
 fibroblastic reticular network 115
 fibroblasts 10, 109, 110, 147, 161
 fibrosis 78, 79, 87, 280, 305
 ficolins 152, 153, 155, 156
 filariasis 53
 first-set rejection 302
 fish 130
 FK506 196, 304
 flagellin 134, 136
 flow cytometry 121, 122, 146, 206, 233
 Flt3 170, 171
 fluid-phase endocytosis 15
 fluorescence 188
 fluorescence-activated cell sorting (FACS) 178, 233
 foetal red blood cells (RBCs) 235
 foetus 46, 95, 126, 227, 287, 288, 306
 follicles 114, 115, 117, 118, 121–124, 237, 239, 251
 – light and dark areas 237
 – light zone 123, 239
 follicular B cells 22, 217–219, 226, 237, 252, 253
 follicular dendritic cells (FDCs) 23, 114, 122, 124, 130, 197, 207, 237–239, 251
 – processes 237, 251
 – surface 237
 follicular T cells 244, 247
 food 37, 53
 food poisoning 53
 food sensitivity 42
 foreign protein 229
 formylated bacterial peptides 159
 – f-Met-Leu-Phe (fMLP) 158
 FoxP3 66, 199, 213, 272
 – transcription factor 68
 fractalkine receptor 164
 Freund's complete adjuvant 173
 fungi 6, 21, 51, 53, 61, 66, 91, 107, 134, 202
 – fungal infections 67
 – after bone marrow transplantation 92
 – fungal spores 289, 291
- g**
 α -galactosylceramide (α -GalCer) 190
 ganglioside 74
 ganglioside (glycolipid) GM-1 283, 284
 gastric carcinoma 80
 gastro-intestinal (G-I) tract 6, 11, 100, 101
 GATA-3 67, 199, 202
 G-CSF 157, 170
 Gell and Coombs 263
 gene conversion 224
 gene expression 36, 249
 – analysis 249
 generation of diversity 27
 gene rearrangement 271
 gene segments 27, 28, 209, 210, 221, 223
 gene-targeted, knock-out mice 57
 gene therapy 130, 131
 genetic basis 292
 – of immunopathology 276
 – of multiple sclerosis 294
 genetic defects 55, 65
 – in IFN- γ receptor 61
 genetic engineering 47
 genetic markers 278. *See also* single nucleotide polymorphisms (SNPs)
 genetic susceptibility 296
 genome-wide association 278
 – studies 278
 germ-free animals 297
 germ-free mice 226, 293, 298
 germinal centres 123, 124, 244, 249
 – reaction 123, 124, 237, 239, 244
 germline DNA 27, 28
 γ -globulins 218
 glomerular nephritis 288
 glucocorticoids 195
 glycolipids 182, 189, 190
 glycoproteins 7
 GM-CSF 128, 157, 170
 goblet cells 10, 100, 102, 280
 gonorrhoea 55, 157
 good-pasture's syndrome 288
 gp120 52
 G-protein-coupled chemokine receptor (GPCR) 37, 107, 151
 graft rejection 260
 graft-versus-host disease (GVHD) 43, 44, 261, 262, 306, 307
 graft versus leukaemia effect 306
 Gram-negative bacteria 53, 79, 80, 134
 Gram-positive bacteria 53, 80, 134
 granulation tissue 110
 granule 63
 granule-dependent mechanisms 19
 – of killing 203
 granule-independent mechanisms 19
 – of killing 204
 granulocyte-macrophage colony stimulating factor (GM-CSF) 12, 148, 198, 262
 granulocytes 11, 12–14, 18, 34, 127, 157
 – types of 18
 granulomas 12, 54, 79, 144, 297
 granulysin 205, 208
 granzymes 18, 19, 21, 35, 68, 167, 203, 204, 206
 Graves' disease 284, 285
 green monkey disease 59
 growth factors 12, 13, 128, 262
 Guillain-Barré syndrome 283–285, 288, 299
 – pathogenesis 283–285
- h**
 haemagglutinin (HA) 52, 83, 85, 96, 184
 haematopoiesis 11–13, 126, 127, 169–171
 haematopoietic stem cells (HSCs) 13, 127, 128, 169, 294, 306
 haemolytic anaemia 266, 267, 285
 haemolytic disease of new-born 286–288
Haemophilus influenzae 72, 96, 241
Haemophilus influenzae Type B (HIB) 96, 241
 haemorrhage 104
 Hageman factor 154
 hagfish 224
 hapten-carrier system 244
 haptens 225, 244
 harderian gland 130
 harmful-harmless discrimination 37
 harmless antigens 37
 Hashimoto's thyroiditis 130, 284, 285
 hay fever 17, 42, 263, 279, 283, 299
 healing 8, 15, 34, 64, 87, 88, 104, 107–111, 134, 145, 149, 201, 305
 – of an infected wound 110
 – excessive healing response – cirrhosis 111
 – of a sterile wound 109
 heat-shock proteins 137, 208
Helicobacter pylori 72, 73, 80, 196
 helminths 66, 72
 helper T cells 33, 237
 hen egg lysozyme (HEL) 255
 heparan sulphate 137
 hepatitis 55, 81
 hepatitis B 55, 86, 96, 110, 309
 hepatitis B vaccine 95
 hepatitis B virus 88
 hepatitis C 55, 87, 88, 110
 hepatitis viruses 111
 hepatocytes 93, 94, 110
 hereditary periodic fevers 141
 herpes simplex virus (HSV) 6, 52, 140, 196, 234
 – infection 234
 herpes viruses (HHV-8) 18, 63, 90, 165
 high endothelial venules (HEVs) 114, 115–117, 121, 191, 237
 higher affinity receptors 238, 248
 high/low responders 185
 histamine 17, 63, 65, 72, 106, 147, 152, 264, 279
 histocompatibility 180. *See* major histocompatibility complex (MHC)
 histone modification 277
 HIV. *See* human immunodeficiency virus
 H-2K 179
 HLA 179, 300
 HLA-A 179
 HLA-B 179
 HLA-B27 299
 HLA-C 179
 HLA-DM 179, 186, 187
 HLA-DO 179, 187
 HLA-DP 179
 HLA-DQ 179
 HLA-DR 179
 HLA-E 179, 182
 HLA matching 304
 H-2M 179, 186, 187
 homeostasis 50
 homing 24
 homologous recombination 57
 host defence 5, 6

- against infection 5, 6, 57
 - host–pathogen relationships 59
 - balance 59
 - house dust mites 280
 - human basophils 227
 - human genome project 220, 278
 - human haematopoietic stem cells (HSCs) 128, 294
 - human herpes virus 88, 308
 - human immunodeficiency virus (HIV) 2, 6, 41, 45, 50, 52, 55, 59, 72, 82, 88, 90, 92, 93, 196
 - escape phase 310
 - immunological events in 91
 - infection, viral events 91
 - human immunoglobulin transgenic mice 255
 - humanization 47
 - humanized mice 294, 296
 - humanized monoclonal antibodies 255
 - human papilloma virus (HPV) 3, 45, 88–90, 308, 309
 - human polio virus receptor (PVR) 52, 83
 - hyaluronic acid 137
 - hybridomas 47, 229, 231, 232
 - hybrid resistance 306
 - hydrochloric acid 101
 - hydrogen peroxide 61, 62, 78, 159, 160
 - hygiene hypothesis 278
 - hyperacute allograft rejection 302
 - hyper-IgM (HIGM) syndrome 56, 69, 246
 - form 250
 - hypersensitivity diseases 41, 42, 260, 263
 - hypersensitivity pneumonitis 289
 - hypersensitivity reactions 263, 266, 267, 283
 - immediate, and delayed-type 265
 - hyperthyroidism 220, 266, 285, 286, 299
 - hypochlorous acid (HOCl) 61, 160
 - hypotension 80, 167, 169, 281
 - hypothalamus 34, 108, 144, 167
 - hypothyroidism 285, 286
 - hypoxia 275
- i**
- I-A 179
 - Ia antigens 185
 - ibuprofen 291
 - ICOS 200
 - identical twins 33, 301
 - IF1H1-MDA5 gene 292
 - IFN- α 34, 81, 143, 150
 - IFN- β 34, 81, 143
 - IFN- γ 16, 21, 34, 62, 64–66, 68, 78, 82, 85, 86, 143, 144, 150, 162–165, 182, 184, 191, 198, 199–202, 204, 205, 208, 247, 278
 - IFN- γ receptor 62
 - IFN-regulated factors (IRFs) 138
 - IFN regulatory factor 5 gene 278
 - IFNs 143
 - IgA antibodies 35–37, 65, 69, 71, 74, 80, 83, 84, 87, 95, 102, 125, 130, 201, 214, 219, 225, 227–230, 241, 247
 - deficiency 69
 - functions 71
 - maternal IgA 44
 - maternal IgG 44
 - transport onto mucosal surfaces 228
 - IgA lymphoblasts 228
 - IgD antibodies 35, 37, 69, 219, 226, 227
 - IgE antibodies 35–37, 42, 65, 66, 69, 71, 201, 203, 219, 227, 229, 233, 247, 248, 263–266, 279, 282, 286
 - cell-bound 279
 - in defence and disease 266
 - functions 72
 - production 279
 - synthesis 279
 - IgG3 241
 - IgG2a 202, 247, 248
 - IgG antibodies 35–37, 67, 69, 71, 83, 84, 219, 227, 264, 266, 268, 283, 289, 290
 - in defence and disease 267
 - deficiency 69
 - functions 71
 - synthesis 283
 - IgG anti-tetanus toxin antibody response 74
 - IgH and TCR β genes 28
 - IgL and TCR α genes 28
 - IgM antibodies 35–37, 69, 70, 77, 219, 224–227, 237, 241, 264, 266, 268
 - in defence and disease 267
 - functions 70
 - IL-1 84, 105, 108, 144, 152, 167, 169, 172
 - IL-1 α 144
 - IL-1 β 141, 144
 - IL-2 194, 195, 199, 202, 203, 293, 297
 - IL-3 12, 148, 170
 - IL-4 34, 65, 66, 148, 170, 191, 198, 199–201, 203, 204, 228, 244, 247, 248, 279, 281, 282
 - IL-5 67, 148, 199, 203, 228, 247
 - IL-6 105, 108, 144, 167, 169, 198, 199, 201, 244
 - IL-7 209
 - IL-9 203
 - IL-10 109, 145, 214, 228, 244, 278, 297, 309
 - IL-12 62, 64, 144, 163, 164, 199, 200
 - IL-13 65, 67, 149, 199, 203, 247, 281
 - IL-17 66, 67, 201, 202, 204
 - IL-18 141, 144, 199
 - IL-21 199
 - IL-23 144, 199, 201, 294
 - IL-1 receptor 138
 - IL-2 receptor 68, 198, 199, 278, 294
 - IL-7 receptor 294
 - IL-8 receptor 164
 - IL-23 receptor 278
 - IL-1 receptor antagonist 141, 142, 144
 - immediate-type hypersensitivities 43, 265
 - immune-based therapies 44
 - immune cells, origin of 12
 - haematopoiesis 12
 - lymphopoiesis 12, 13
 - immune complexes 35, 36, 42, 155, 264, 266, 268, 290, 291, 297
 - in defence, and disease 268
 - local deposition of immune complexes 267, 289
 - immune complexes (type III hypersensitivity) 266
 - immune complex-related diseases 157, 158, 290, 291
 - immune defects 139
 - in killing bacteria 162
 - in migration 161
 - in TLR Signalling 138
 - immune dysregulation, polyendocrinopathy, enteropathy X-linked (IPEX) 213, 260
 - immune effector mechanisms 285
 - immune recognition 6, 7
 - immune regulation 64
 - immune-related sensitivities 41–43, 260, 273, 275, 277
 - immune-related therapies 262
 - immune response (IR) genes 185
 - immune responses 1, 259
 - coordination of 23, 24
 - and disease 37
 - against infection 39
 - causing damage 39, 40
 - molecules involved in 25
 - immune surveillance 3, 88
 - immunity 1, 8. *See also* adaptive immunity; innate immunity
 - active forms of 95
 - anatomical basis of 9, 10
 - cellular basis of 12
 - defects in, causing serious infections 40, 41
 - and disease, immunopathology 259–261
 - evasion 44
 - evolution 5, 37, 40, 49, 59, 99, 111, 130, 133, 149, 157, 169, 175, 180, 217, 218, 224, 259
 - molecular basis of 24
 - passive 95
 - plants 5
 - stages of 8, 9
 - vaccines 94–97
 - immunoblotting 139
 - immunocytochemistry 233
 - immunodeficiencies 40, 41, 55, 56, 126, 195, 228, 259, 260, 308
 - immunoglobulin genes 221, 223
 - DNA coding for 220
 - immunoglobulin C region genes 245
 - rearrangement 252
 - immunoglobulin, (Ig) heavy (H) and light (L) chains 28
 - immunoglobulin–receptor complex 228
 - immunoglobulins 218, 224. *See also* antibody(ies)
 - domains 24, 218
 - genes, generation 223
 - heavy (H)/light (L) chains 218
 - isotype 251
 - polypeptide chains 218
 - structure 222
 - superfamily 24, 218, 248
 - immunological ignorance 213
 - immunological interventions, in disease 3
 - immunological memory 6, 21, 124
 - immunological synapse 193, 194, 196, 203, 206
 - immunological tools, for diagnosis 3
 - immunopathology 259, 260
 - allergic diseases (type I hypersensitivity reactions) 279–283
 - animal studies, and genetic susceptibility 278
 - cell-mediated (type IV) hypersensitivity reactions 291–300
 - concordance in twin studies 277
 - diseases caused by actions of antibody on cells (type II hypersensitivity reactions) 283–288
 - diseases caused by immune complexes (type III hypersensitivity reactions) 288–291
 - genetic basis 276–278

- immunological diseases, increasing incidence 278
 - lymphocyte activation 272–276
 - in immunological diseases 272–276
 - mechanisms 264
 - therapy 278–300
 - immunoprecipitation 139, 142, 188
 - immunoproteasome 184, 186
 - immunoreceptor tyrosine-based activation (ITAMS) 166, 193, 241
 - immunoreceptor tyrosine-based inhibition motifs (ITIMS) 166, 242, 248
 - immunosuppression 90, 291, 297, 304, 305
 - immunosuppressive agents 195
 - immunosuppressive drugs 262
 - immunosuppressive therapy 88, 91
 - immunosurveillance 308
 - immunotherapy 215, 216, 254, 261
 - adoptive cell therapy 45, 215, 216, 262
 - infections and immunopathological diseases 216
 - T cell vaccines 215
 - for cancer 309
 - inbred strains 301
 - indirect pathway 302, 303
 - indoleamine deoxidase (IDO) 306
 - indomethacin 148
 - inducer cells 130
 - infections 1, 5, 40, 104, 178, 274. *See also* pathogens
 - agents 6
 - and disease 2, 54, 55
 - and immunity in action 69–94
 - ingestion 51
 - inhalation 51
 - injection (sexual transmission) 51
 - subclinical 8
 - infectious agents 6, 49
 - recognition of 25
 - infectious diseases 40, 51
 - transmission 51
 - inflammasomes 141, 172
 - and autoinflammatory diseases 141, 142
 - inflammations 7, 9, 10, 11, 13, 27, 35, 42, 104, 107, 109, 110, 122, 134, 147, 150, 151, 198, 264, 288
 - acute, in skin 103
 - features of 103
 - healing and repair in 109–111
 - inflammatory mediators 279
 - regulation of 109
 - repair in chronic inflammation 110, 111
 - resolution 64
 - sites 11, 12
 - systemic effects of 108, 168
 - inflammatory bowel disease 145, 277, 296, 298
 - infliximab 297
 - influenza 21, 52, 82, 83, 86
 - epidemics 85
 - haemagglutinin 52, 166, 184
 - H1N1 (swine flu) 85
 - H5N1 (bird flu) 85, 86, 96
 - immunity to 87
 - matrix protein 184
 - pandemics 85
 - influenza viruses 6, 81, 82, 85, 104, 184, 185, 234
 - life cycle 85
 - matrix protein 184
 - innate agonist receptors 24
 - innate immune mechanism 226
 - innate immune system 95, 103, 208, 272
 - innate immunity 5–7, 13, 24, 27, 34, 55, 58, 93, 112, 133, 145, 259
 - anatomical organization 112
 - cell-associated PRRs
 - promoting uptake 136, 137
 - signalling to nucleus 136, 137
 - cells, directly link 13, 14
 - cellular distribution of PRRs 142
 - cellular effectors, recruitment of 106
 - cytokines in 34, 143–145
 - defects in 55
 - effects of inflammatory mediators, on distant tissues 108
 - features of inflammation and 103
 - functional anatomy of 103–111
 - induction of 133
 - innate immunity 133
 - leukocyte function, in inflammation 107
 - leukocyte recruitment, in acute inflammation 106
 - local inflammatory responses and 105
 - mechanisms of 58–65
 - in other species 169
 - pattern recognition, and danger 133, 134
 - recognition in 7, 8
 - recruited effectors of 153–169
 - responses to
 - infection 104, 105
 - trauma 104
 - soluble effector molecules, recruitment of 106
 - structure and function of TLRs 137–141
 - tissue-resident cells of 145–153, 147
 - inositol triphosphate (IP₃) 194
 - insect bites 53
 - insects 169
 - insulin 211, 292
 - insulin-dependent (type I) diabetes 42
 - insulin-secreting cells 293
 - integrins 24, 26, 106, 107, 151, 154
 - integrin $\alpha_4\beta_7$ 191
 - intercellular cell adhesion molecule (ICAM-1) 193
 - interferons (IFNs) 34, 262
 - interferon (IFN)- γ 108
 - interferon (IFN)- γ receptor 57
 - interferon (IFN)-type I 23
 - interleukin (IL)-1 receptor 137
 - intestinal epithelial cells 79
 - intestinal infections 69
 - intestinal inflammation 79
 - intestinal spiral valve 130
 - intestinal worms 18, 51, 69, 91, 92
 - intestines 99, 102, 113, 227, 307
 - intracellular bacteria 53, 62, 65, 68
 - intracellular cytokine staining 144
 - intracellular flow cytometry 146
 - intracellular signalling 24, 29, 30, 139, 194, 195
 - intravenous immunoglobulin (IVIG) therapy 91, 95, 261, 284, 288
 - intra-vital microscopy 191, 237
 - intrinsic antigens 260
 - invariant chains 186, 187, 188
 - invariant NKT (iNKT) cells 20, 175, 176, 182, 189, 190, 210
 - invariant pre-T α chain 210
 - ionizing irradiation 161
 - IP₃ 195
 - IPEX (Immune dysregulation, Polyendocrinopathy, Enteropathy X-linked) 66
 - IRAK-4 140
 - IRFs 140, 143
 - iron 160
 - Islets of Langerhans 292, 293
 - isogeneic 300, 301
 - isograft 300, 301
 - isotypes 220
 - exclusion 224, 252
 - switching 238, 239, 245–247
 - ITAM motifs 177, 194, 248
- j**
- JAKs 38
 - JAK–STAT pathway 36, 38, 143, 144
 - JAM assay 151
 - jawless 224
 - J chain 224, 225, 227
 - Jenner 95
 - joints 290, 297
 - jumping genes 175
 - junctional diversity 211, 223
- k**
- Kaposi's sarcoma 88, 90, 308
 - karyotypic markers 128
 - keratin 99, 100
 - keratinized 101
 - kidney 290
 - kidney allograft 275
 - kidney transplantation 88, 300, 308. *See also* allograft rejection
 - killer cell inhibitory-like receptors (KIRs) 166
 - killer lectin-like receptors (KLRs) 166
 - kinases 139
 - kinin cascade 154
 - knock-out mice 141, 145
 - Koch's postulates 72, 73
 - Kupffer cells 149
- l**
- lactacystin 184
 - lactation 38
 - lactobacilli 103
 - lactoferrin 160
 - lampreys 224
 - Langerhans cells 101, 197
 - large granular lymphocytes 164
 - large intestine 102
 - laser capture micro-dissection 249
 - Lassa fever 59
 - LAT 194
 - latency 52
 - late proteins 52, 85
 - Lck 194
 - LCMV 183
 - lectins 25
 - Legionella* 63, 149
 - Legionnaire's disease 63
 - Leishmania* 53, 76
 - Leishmania major* 200, 201, 204

- leprosy 6, 16, 72, 97, 201
 - leucine-rich repeats (LLRs) 137
 - leucocidins 160
 - leukaemias 44, 91, 131, 306
 - leukocyte adhesion deficiency (LAD) 56, 58, 107, 162
 - leukocyte binding 105
 - leukocyte emigration 154
 - leukocyte-endothelium interactions 106
 - leukocyte function in inflammation 107
 - leukocyte receptor complex (LRC) 166
 - leukocyte recruitment 34, 105, 106
 - leukocytes 10, 14, 25, 61, 64, 106, 108
 - adhesion deficiency 107
 - endothelium interactions 106
 - extravasation, post code principle for 26
 - function in inflammation 107, 108
 - recruitment in acute inflammation 106
 - transendothelial migration 151
 - leukocyte transendothelial migration 151
 - leukotrienes 63, 65, 144, 147, 158, 159, 265, 279
 - Leydig's organ 130
 - ligand-receptor binding 225
 - light (L) chains 218, 220
 - limiting dilution 232
 - linkage analysis 278
 - lipid antigens 188. *See also* antigens
 - CD1 molecules 188–191
 - invariant NKT (iNKT) cells 190
 - lipid mediators 17, 64, 65, 118
 - lipid rafts 193
 - lipopolysaccharide (LPS) 80, 130, 134, 136, 144, 167, 169, 191, 239, 240, 280, 283
 - bacterial lipopolysaccharide (LPS) 284
 - lipoteichoic acid 80, 134, 136, 167, 169
 - lipoxins 109
 - Listeria* 62, 63, 69
 - liver 11, 12, 34, 108, 144, 167, 168, 307
 - cancer 88, 309
 - failure 86, 88
 - transplant 87
 - lobar pneumonia 53, 76, 77
 - long-acting thyroid stimulator (LATS) 284, 285
 - low-density lipoprotein 136
 - LPS. *See* lipopolysaccharide
 - LPS binding protein (LBP) 136
 - LRR domain 138
 - lungs 6, 100, 267, 289
 - lymph 10, 11
 - lymphatic 10, 111, 305
 - lymph nodes 9–11, 52, 77, 87, 111–115, 118, 121, 124, 129, 130, 215
 - antigen delivery to 118
 - antigen transport to 119
 - B cell responses in 121
 - cellular and molecular streams in 117
 - shut down 117
 - and lymphocyte recruitment 117, 118
 - structure 114
 - and function 114
 - lymphocytes 6, 8, 13, 14, 19, 76, 111, 273
 - activation 121, 272
 - in immunological diseases 271–276
 - signal 1 30, 31, 192, 241, 272
 - signal 2 31, 192, 194, 241, 272
 - signal 3 192
 - signal 4 192
 - antigen receptors, diversity, generation of 27, 28
 - co-stimulation of 31
 - development 270
 - in health and disease. 273
 - recirculation 11, 112, 116, 117, 121, 191
 - in rats 116
 - recruitment 117, 118, 120, 121
 - lymphocytic choriomeningitis virus (LCMV) 182
 - lymphoid cells 12, 128, 175
 - lymphoid tissues 8, 11, 130
 - organizer cells 130
 - in other species 130
 - lymphopenia 293
 - lymphopoiesis 12, 126, 127
 - lymphotoxin 130
 - lysosomes 15, 58, 59, 60, 152
 - lysosomal enzymes 158
 - lysosomal proteases 61
 - lysozyme 101, 160
- m**
- macromolecules 10
 - macrophages 9–13, 15, 16, 27, 34, 42, 52, 60, 62, 81, 101, 102, 104, 108, 109, 114, 118, 121, 125, 127, 142, 143, 147, 149, 151, 152, 182, 201, 232, 235, 238, 269, 292, 293, 295, 304, 305
 - activated 15, 16, 21, 37, 64, 66, 78, 82, 86, 108, 122, 143, 150, 162, 201, 263, 264, 268, 292, 296
 - activator 34
 - alternative activation of 21, 67
 - alveolar 149
 - evasion mechanisms 63
 - inflammatory, functions of 163
 - inflammatory macrophages 15, 16, 75, 77, 84, 109, 149, 150, 155, 163
 - macrophage-alternatively activated 282
 - macrophage mannose receptor 134
 - macrophage-resident, and inflammatory 120
 - phagocytic receptors on 149
 - recruited, and inflammatory homeostasis 162, 163
 - recruited macrophages 162
 - recruited (or elicited) macrophages 13
 - resident 149, 150
 - role 237
 - types of 16
 - macropinocytosis 59
 - magnetic beads 142
 - major histocompatibility complex (MHC) 7, 19, 26, 28, 31–33, 43, 166, 175–177, 179, 181, 182, 193, 194, 210, 271, 278, 289, 292, 294, 300–302, 304, 307
 - alloreactivity 300
 - associations 285
 - bound peptides 181, 272
 - class I-associated peptides 181
 - classical 179–182
 - CD4/CD8 interactions 180
 - cellular distribution 182
 - peptides bind to 180
 - classical molecules 179–182
 - antigen processing, class I/II presentation 182–187
 - cellular basis of antigen processing, and presentation 182
 - cellular distribution of 182
 - cross-presentation 187, 188
 - peptides bind to 180
 - subversion of antigen processing, by pathogens 188
 - types 32
 - class II 238, 243, 292
 - class II α, β 187
 - class II alleles 281
 - class II antigens 185
 - class II biosynthesis 188
 - class II molecules 32, 176, 180, 182, 186, 244, 296
 - class II peptides 181
 - class II presentation 185
 - foreign antigens, endosomal degradation of 185, 186
 - peptide loading 186, 187
 - class II processing 187
 - class I molecules 32, 68, 85, 166, 176, 180, 182, 255, 311
 - class I presentation 182
 - peptide editing 184, 185
 - peptide-loading complex 184, 185
 - proteasome 184
 - TAP transporter 184
 - function in presenting antigens 32, 33
 - genes 33
 - H-2 179, 300
 - H-2D 179
 - H-2O 179, 187
 - human leukocyte antigens (HLA) 179
 - human/mouse, genetic organization 179
 - I-E 179
 - non-classical 182
 - peptide-binding 180, 181
 - peptide-major histocompatibility complex class II processing 187
 - peptides interactions 180
 - polymorphisms 180, 181
 - restriction 176, 183, 210
 - role 295
 - self-non-self discrimination 180
 - T cell receptors (TCRs) 176
 - T cell recognition 32
 - tetramers 206, 207
 - malaria 6, 53, 91, 92, 94, 97
 - malignant tumours (cancer) 2, 5, 44, 45, 80, 175, 216, 254, 275, 306, 307
 - bacteria causing 80
 - mutation rate 44
 - mammalian target of rapamycin (mTOR) 195, 305
 - mammary gland 11, 227
 - mannose-binding lectin (MBL) 61, 155, 156
 - mannose receptor 137
 - Mantoux test 76, 79, 265
 - MAP kinase 140
 - marginal sinus 237
 - marginal zone 21, 125, 126, 237
 - marginal zone B cells 22, 69, 125, 218, 219, 237, 252, 253
 - marginal zone macrophages 237
 - marginal zone metallophil 237
 - MASP-1 and -2 155
 - MASP proteases 156
 - mast cells 9, 10, 13, 17, 34, 36, 43, 47, 63, 65–67, 71, 101, 102, 104, 105, 127, 142, 147, 148,
 - cellular distribution of 182
 - cross-presentation 187, 188
 - peptides bind to 180
 - subversion of antigen processing, by pathogens 188
 - types 32
 - class II 238, 243, 292
 - class II α, β 187
 - class II alleles 281
 - class II antigens 185
 - class II biosynthesis 188
 - class II molecules 32, 176, 180, 182, 186, 244, 296
 - class II peptides 181
 - class II presentation 185
 - foreign antigens, endosomal degradation of 185, 186
 - peptide loading 186, 187
 - class II processing 187
 - class I molecules 32, 68, 85, 166, 176, 180, 182, 255, 311
 - class I presentation 182
 - peptide editing 184, 185
 - peptide-loading complex 184, 185
 - proteasome 184
 - TAP transporter 184
 - function in presenting antigens 32, 33
 - genes 33
 - H-2 179, 300
 - H-2D 179
 - H-2O 179, 187
 - human leukocyte antigens (HLA) 179
 - human/mouse, genetic organization 179
 - I-E 179
 - non-classical 182
 - peptide-binding 180, 181
 - peptide-major histocompatibility complex class II processing 187
 - peptides interactions 180
 - polymorphisms 180, 181
 - restriction 176, 183, 210
 - role 295
 - self-non-self discrimination 180
 - T cell receptors (TCRs) 176
 - T cell recognition 32
 - tetramers 206, 207

- 151, 200, 229, 233, 236, 248, 263, 264, 266, 279–282
- activation, degranulation and secretion 65
 - functions 148
 - high-affinity FcRs 233
 - mediators produced by 17
- matrilysin 146
- M cells 125, 228, 230
- MCSF 170
- MD-2 136, 280
- measles 21, 56, 81, 83
- medulla 114, 123, 124, 129
- medullary cords 237
- medullary epithelial cells (MECs) 129, 211, 212
- megakaryocytes 12
- melanocytes 308
- melanomas 308, 309
- membrane attack complex (MAC) 155, 156
- membrane-bound IgM 69
- membrane cofactor protein (MCP) 157
- memory lymphocytes 9, 21, 22, 31, 121, 123, 124, 207, 208, 217, 237, 238–240, 245, 250, 251, 265
- responses 22
- meningitis 75, 96, 157
- meningococcus 55
- mesangial cells 149
- metastasis 44, 80, 89, 307
- metazoa 6, 50, 53, 91
- metazoan worms 18
- Metchnikoff 149
- Meth A sarcoma 309
- methicillin-resistant *Staphylococcus aureus* (MRSA) 2, 55
- methyl dopa 285, 287
- methylprednisolone 303
- MHC. *See* major histocompatibility complex
- MHC-restriction 271
- MIC-A 166, 179, 182, 208
- MIC-B 166, 179, 182, 208
- microbes 6, 40
- microbial evasion strategies 196
- microbial macrophage, evasion mechanisms 63
- microglial cells 149
- β_2 -microglobulin 179, 180, 186
- milk 46, 95
- minor histocompatibility antigens 300, 301
- minor transplantation antigens 302
- missing self hypothesis 166
- mitogens 130
- mobile DNA elements. *See* jumping genes
- modified virus Ankara (MVA) 96, 173
- modulation of adaptive immunity 235
- molecular basis of immunity 24
- molecular mimicry 283–285
- molecular patterns (DAMPs) 104
- molecules, involved in transmigration 26
- monoclonal antibody(ies) 45–47, 178, 193, 229–231, 233, 248, 256, 261, 305
- production 231
 - screening 232
 - technique 230, 231
 - uses in immunology 233
- monocyte-derived DCs 197
- monocytes 11, 12, 13, 15, 62, 75, 77, 78, 80, 84, 103, 107, 109, 118, 127, 148–150, 162, 163, 169, 197, 216, 234
- mononuclear cells 302
- mononuclear infiltrate 76
- mosquitoes 53, 93, 94
- mosquito nets 93
- motor neurons 81–83
- mRNA 201
- mRNA alternative splicing 226
- mTOR 195, 196
- mucosal 191
- mucosal addressin cell adhesion molecule (MadCAM) 191, 228
- mucosal antibody 69
- mucosal-associated lymphoid tissues (MALTs) 11, 111, 124
- mucosal immunity 228, 229
- mucosal surfaces 100, 228
- mucosal tissues 10, 11, 18, 63, 71, 100, 207
- intestine 102
 - respiratory tract 102
 - surface areas of 100
- mucus 11, 18, 100, 102, 280
- multi-cellular metazoa 263
- multi-cellular parasites 201
- multi-photon fluorescent microscope 119
- multiple sclerosis 294–296
- evidence from animal studies 294–296
 - genetic basis 294
 - like disease in humanized mice 296
 - pathogenesis 294
 - treatment 296
- multi-potent haematopoietic stem cells (HSCs) 128, 169
- multipotent (pluripotent) stem cells 12, 127, 270
- muramyl dipeptide 137, 296
- muscle 108
- muscle and adipose tissue 108
- mutations 44, 45, 86, 91, 307, 308
- mutualism 53
- myasthenia gravis 41, 266, 267, 285, 288
- mycobacteria 6, 16, 53, 62, 76, 200
- Mycobacterium bovis* 77
- Mycobacterium leprae* 72, 201
- Mycobacterium tuberculosis* 50, 53, 54, 62, 63, 76–79, 107
- Myd88 138–140, 144
- myelin 284, 294
- myelin basic protein 294, 295
- myelin basic protein peptide 296
- myeloid cells 12, 127, 128, 169–171
- myelomas 220, 229, 231
- myeloperoxidase 159, 160
- myelopoiesis 12, 126, 171
- n**
- NADPH oxidase 158, 159, 162
- Nalp3 141
- nasal-associated lymphoid tissues; NALTs 111
- nasal olfactory receptors 224
- nasal tolerance 214
- nasopharyngeal carcinoma 88
- natalizumab 296
- natural antibodies 21, 60, 102, 226, 238
- natural barriers 6, 8, 14, 99, 100
- commensal flora 102, 103
 - gastro-intestinal tract 101
 - mucosal surfaces 100, 101
 - respiratory tract 101
 - skin 100
 - uro-genital tract 101, 102
- natural IgM antibodies 219
- natural killer (NK) cells 12–14, 18, 19, 34, 62, 64, 81, 82, 91, 108, 127, 144, 150, 151, 163, 166, 167, 175, 188, 202, 234, 236, 248, 270, 306
- activating, and inhibitory receptors 166
 - functions 64
 - HLA-E 182
 - human NK cell deficiencies 164
 - life history 164
 - recognition and activation 167
 - subsets 163, 165
 - functions of 165
- natural regulatory T cells 213
- natural selection 49, 133
- necrosis 150, 151, 153, 275
- assessment of 153
- needle-stick accidents 72
- Nef 91, 196
- negative costimulatory molecules 311
- negative selection process 129, 178, 211, 212, 253, 270, 271
- Neisseria gonorrhoeae* 55
- Neisseria* infection 157
- Neisseria meningitidis* 55, 73, 75, 96, 157
- neonatal FcR (FcRn) 227, 248
- neonatally thymectomized mice 244
- neonatal thymectomy 129
- neonate 46
- nerves 75, 283
- neuraminidase (NA) 85, 184
- neutralization 36, 37, 69–71, 73, 81, 84, 231, 265, 266
- neutrophils 12, 14, 16, 17, 18, 21, 58, 61, 63, 66, 75–77, 103, 106–109, 118, 120, 146, 148, 149, 154, 157, 158, 160, 161, 202, 204, 226, 232, 235, 268, 289, 301
- anti-microbial functions of 158
 - bacterial killing by 159
 - chemotaxis 159
 - defects 161, 162
 - killing by 17
 - microbicidal mechanisms 62
 - neutrophil chemotaxis 159
 - neutrophil defects 161
 - neutrophil extracellular traps (NETs) 17, 61, 62, 158, 160
 - neutrophilic polymorphonuclear leukocytes (PMNs) 157
 - neutrophil microbicidal mechanisms 62
 - phagosomal killing by 160
- NFAT 194, 195, 304
- NF- κ B 138, 140, 144, 194, 195, 242
- nitric oxide 80, 144, 152, 169, 198
- NKG2D receptor 208
- NK1.1 molecule 189
- NKT cells 20, 200, 270
- NLRs 141
- NOD2 296
- NOD-like receptor (NLR) family 27, 137, 141, 190
- NOD mice 292, 293
- non-classical MHC molecules (HLA-C and -E) 32, 91, 182
- non-infectious disease, immunotherapy 254
- non-lymphoid 8
- non-obese diabetic (NOD) 278

- non-self 8
 non-steroidal anti-inflammatory drugs (NSAIDs) 265, 291, 298
 norovirus 81
 notch 214
 novel molecules 233
 nucleic acids 135
 nucleoprotein 184, 185
 nucleotides 223
 – N-regions 224
 – P-regions 224
 nude mice 178, 302
 nutrients 10
- O**
- occupational hypersensitivities 43, 289
 occupational sensitivities 43
 oedema 12, 75, 103, 106, 147, 161, 264, 265
 olfactory receptors 224
 oligodendrocytes 294
 Omenn syndrome 210
Onchocercidae 53
 oncofoetal antigens 307, 308
 oncogenes 89
 oncogenic virus 44, 89
 opportunistic infections 50, 56, 65, 90, 92
 opsonins 37, 61, 69, 70, 106, 155, 201, 226
 opsonization 35, 36, 60, 69, 71, 81, 84, 155, 202, 232, 235, 265, 266, 286
 opsonizing antibodies 65, 66
 oral/mucosal tolerance 283
 oral tolerance 200, 214
 organs of immunity, development of 126
 osmotic/colloidal lysis 155
 osteoarthritis 297
 osteoclasts 149
 ovalbumin (OVA) 214, 281
- P**
- pain 103, 154
 Palade bodies 154
 palindromic sequences 210, 223
 pandemics 85, 86
 paneth cells 102, 146, 296
 papain 220, 222
 papilloma virus 88
 paracortex 114, 117
 paracrine 33, 34
 paralysis 83
 parasites 6, 14, 17, 18, 53, 55, 63–65
 – generalized life cycles 55
 – infections, pathogenesis of 92–94
 – pathogenesis of 92–94
 parasitic infections 18, 21, 69, 71, 72, 91
 parasitism 53
 passenger cells 302, 303
 passive defence 6
 passive immunity 46, 95
 passive transfer 69, 279
 pasteur 96
 pathogen-associated molecular patterns (PAMPs) 7, 8, 86, 105, 134, 135, 147, 154, 272, 274
 pathogenicity, mechanisms of 70
 pathogen neutralization 234
 pathogens 49, 51
 – bacteria 52, 53
 – life cycles of 54
 – causing diseases, types of 50
 – definition 49
 – fungi 53
 – and infectious disease 49
 – parasites 53, 54
 – pathogenicity, mechanisms 70
 – protein 284
 – viruses 50–52
 pattern recognition molecules (PRMs) 27, 133, 134
 pattern recognition receptors (PRRs) 7, 8, 15, 22, 23, 25–27, 58, 65, 102, 104, 105, 111, 134, 135, 137, 141, 147, 272
 – cell-associated PRRs
 – promoting uptake 134
 – signal to nucleus 136
 – cellular distribution of 142
 – cellular locations of 135
 – functions of 137
 – signalling 136
 – types and locations of 27
 PD-1 192, 195
 peanut allergy 280
 penicillin 286
 pentamer 69
 peptic ulcers 72, 73
 peptide editing 184
 peptide-loading complex 184, 186
 peptide-MHC complexes 7, 22, 23, 29, 30, 32, 43, 117, 177, 191, 194, 206, 221, 243, 271
 – class II complexes 33
 – class I molecules 33
 peptides 7, 28, 32, 180, 181
 perforin 18, 19, 21, 35, 68, 167, 206, 208
 peripheral nerves 74, 284
 peripheral node addressin (PNA_d) 191
 peripheral tissues 8, 10, 11
 peristalsis 101, 102
 peritoneal cavity 253
 permeability 34, 104, 106
 pertussis infection 73
 pertussis (whooping cough) toxin 107
 Peyer's patches 11, 12, 111–113, 115, 121, 124, 125, 127, 129, 130, 191, 224, 228, 230, 237, 247
 phage display 255
 phagocytes 6, 9, 11, 13–15, 23, 35, 41, 56, 58, 226
 phagocytic receptors 149
 phagocytosis 13, 15, 27, 52, 58–60, 62, 75, 134, 149, 152
 – coiling 63
 – by macrophages 152
 phagolysosomes 15
 phagosomes 15, 32, 58, 59, 62, 152
 phosphatases 139
 phosphatidylinositol 3-kinase (PI3) kinase/Akt pathway 195
 phosphatidylserine 151, 153
 phospholipase C γ 2 241
 phospholipids 154, 182
 photoaffinity labelling 221
 pinocytosis 15, 59, 60
 placenta 36, 47, 95, 227, 285, 287, 288
 plants 169, 180
 plasma cells 9, 14, 21, 29, 69, 102, 114, 121, 123–125, 217, 238–240, 244, 245, 297
 – long-lived plasma cells 250, 252
 – maintenance 245
 – production 244
 plasmacytoid 116
 plasmacytoid dendritic cells (pDCs) 22, 34, 81, 86, 117, 143, 164, 197, 198
 plasma membranes 135, 234
 plasmapheresis 261, 283, 284, 287
 plasmin 154
Plasmodium 53, 93
Plasmodium falciparum 53, 92, 93
 platelet derived growth factor (PDGF) 109, 110, 162
 platelets 109, 127
Pneumocystis 91
Pneumocystis jirovecii 50, 56, 178
 pneumonia 75
 point mutations 248
 poison ivy 214
 polarization of CD4 T cells 276
 polarized responses 201
 poliomyelitis 81
 – polio vaccine 81–83
 polio virus 52, 81
 – vaccine 82, 83
 pollen 299
 polyclonal antibodies 229
 – response 229
 polyethylene glycol 231
 poly-immunoglobulin receptor 228
 polymeric carbohydrate 125
 polymorphisms 32, 33, 179, 278
 polysaccharide capsule 76
 polysaccharides 69
 pores 68, 146
 positional cloning 136
 positive selection 129, 210, 212, 270, 271
 post-capillary venules 105
 post code principle 25, 26, 106, 115, 151
 P-regions. *See* palindromic sequences
 pregnancy 38
 primary follicles 237
 primary immunodeficiency diseases 41, 44, 55, 95
 primary lymphoid organs 8, 11, 126, 127
 primary responses 22, 243
 prions 5, 50
 pro-inflammatory cytokines 23, 34, 93, 105, 136, 140, 142, 144, 248, 265
 prokaryotes 50
 promoter 196
 prophylactic vaccination 44, 45, 94
 propidium iodide (PI) 151, 153
 prostaglandins 63, 65, 84, 144, 147, 265, 279
 protease inhibitors 186
 proteases 77, 274
 proteasomes 183, 186
 protectin 157
 protein A 161
 protein gp120 52
 protein kinase C (PKC) 241
 protein synthesis 241
 α -proteobacteria 191
 protozoa 6, 50, 51, 53, 66, 68, 91
 P-selectin 152
 pseudo-genes 224
 psoriasis 277
 puberty 38
 pulse-chase labelling 188

- pus 16, 61, 75, 110, 161
 pyogenic (pusforming) bacteria 16, 54, 61, 67, 69, 108, 110, 159, 160, 196, 201, 232, 245
 pyogenic bacterial infections 107, 141, 157, 162, 226, 252
 pyrogenic 75
- q**
 quorum sensing 180
- r**
 rabbits 127, 224
 rabies 50, 51
 Rac 149, 195
 RAC2 107
 RAG-1 210, 221
 RAG-2 210, 221
 RAG gene 223
 – expression 253
 RAG molecules 211
 rapamycin (sirolimus) 196, 305
 reactive oxygen intermediates (ROIs) 16, 17, 61, 62, 78, 141, 150–160, 248
 rearrangement, gene segments 28
 receptor
 – specificity 8
 receptor co-operativity 225
 receptor editing 38, 39, 253, 254
 receptor revision 253
 receptors, affinities 225
 recirculation 20, 113, 208
 recognition 24
 recombinase-activating complex 253
 recombinase-activating gene (RAG) 178, 221
 – defect causing SCID 221
 – endonucleases 221
 – expression 253
 – molecules 211
 recombination signal sequences (RSSs) 210, 211, 221
 recruited effectors of innate immunity 153
 recruited molecules 153
 recruitment 105, 106
 red blood cells (RBCs) 10, 93, 94, 235, 266
 red pulp 125, 126
 regulation
 – of B cell activation 243
 – of complement activation 157
 – of haematopoiesis 170
 – of inflammation 109
 regulatory CD4 T cells 68
 regulatory T cells (T_{reg}) 19–21, 39, 66, 192, 198, 199, 213, 214, 261, 298, 309, 311
 remodelling 34, 150
 reovirus 125
 repair 8, 15, 34, 88, 107, 109, 110, 134, 145, 147, 162, 201
 repertoires 8, 27
 reproductive organs 213
 reservoirs 50, 51, 55
 resident macrophages 13, 15, 105, 149
 resistance
 – to infection 46
 – to re-infection 250
 resolution 75
 resolvins 109
 respiratory burst 162
 respiratory smooth muscle 279
 respiratory syncytial virus 154, 196
 respiratory tract 11, 69, 100–102, 227
 – infections 69
 – mucosal tissues 102
 retinoic acid 247
 reverse transcriptase 90
 reverse transcription-polymerase chain reaction (RT-PCR) 249
 rhesus antibodies 235
 rhesus (Rh) blood groups 286
 rhesus disease (haemolytic disease of the new-born) 235
 rheumatoid arthritis 79, 130, 144, 254, 256, 261, 278, 297–299
 – forms 254
 – pathogenesis 297, 298
 rheumatoid factor 297
 Rho family GTPases 149, 152
 RIG-I-like helicases (RLHs) 137
 RNA-editing enzyme (APOBEC-3G) 91
 RNA helicases 27
 rolling 25, 26
 RORyt 67, 199, 202
- s**
 Sabin polio vaccine 82–84, 95
Saccharomyces cerevisiae 297
 salbutamol 280
 salivary glands 94
 Salk vaccine 83
Salmonella 53, 79, 104, 125, 173, 200
Salmonella typhimurium 53, 80
 sand flies 53
 sarcomas 90, 306
 scaffold protein, BLNK 38, 241
 scarring 75, 78
 Scatchard analysis 225
 scavenger receptors 27, 134, 150
 schistosomiasis 53, 55
Schistosoma cercariae 53
 – schistosomes 55, 104
 – schistomula 234, 236
 SCID (severe combined immunodeficiency) 131, 227
 scrapie 50
 SDS–polyacrylamide gel electrophoresis (PAGE) 140
 sea urchin 169
 sebaceous glands 101
 sebum 100
 secondary follicles 123, 237
 secondary (acquired) immunodeficiency diseases 41, 56
 secondary infections 52, 72, 104
 secondary lymphoid organs 12, 113, 124, 129, 191
 secondary lymphoid tissues 8, 9, 11, 111, 112, 251
 – T cell polarization in 118
 secondary responses 22, 243
 secretory glands 51
 secretory lysosomes 203
 secretory piece 228
 selectin 107
 – E- and P-selectins 154
 L-selectin 208
 selectins 24–26, 106, 151
 self–non-self discrimination 37, 134
 sensitization 302, 303, 305
 sensory nerves, stimulation 264
 septicæmia 80, 161
 septic shock 80, 138, 161, 166, 169
 sequential determinant 30
 sequential epitopes 271
 severe combined immunodeficiency (SCID) 56, 131, 190, 195, 210, 221, 223
 – causes 221, 223
 severe, persistent, unusual or recurrent (SPUR) infections 41, 55, 259
 SH2 domains 36, 38
 sheep 127, 208, 224
Shigella dysenteriae 53
 shingles 52
 shock 280
 SHP phosphatases 242
 sialic acid 52, 83, 85
 sialoadhesin 242
 signalling 140, 243
 – molecules 25
 – pathways 36
 – in B cell activation 242
 – via TLRs 138
 signal transducers and activators of transcription (STATs) 37, 38
 signal transduction 36
 silica 109, 141
 simian immunodeficiency virus (SIV) 72
 single-chain variable fragment (ScFV) 255
 single nucleotide polymorphisms (SNPs) 278
 single-stranded RNA 137
 sinusoid-lining macrophages 288
 sirolimus 305
 skin 6, 100, 101, 103, 191, 207, 290, 302, 307
 – defence barriers 101
 – functions 100
 – grafts sensitization 305
 – surface areas of 100
 – and vascularized organ allografts, sensitization mechanisms 305
 SLE. See systemic lupus erythematosus (SLE)
 Smads 145
 small intestine 101
 smallpox 21, 59, 81, 83, 95
 – vaccination 178
 smooth muscle 17, 64, 72, 280, 281, 283, 305
 sodium cromoglycate 283
 soluble effector molecules 106
 soluble self antigen 255
 somatic gene rearrangement 210
 somatic hypermutation 29, 30, 124, 224, 226, 237–239, 244, 245, 248, 249
 somatic recombination 27, 221
 sore throats 6, 11
 Southern blotting 220, 221
 SP-A 154
 Spanish flu, 1918 86
 spastic paralysis 74, 75
 SP-D 154
 specificity 27, 38
 spiking 119
 spleen 9, 11, 92, 93, 111, 113, 115, 121, 123–126, 129, 130, 218, 237, 240, 253
 – structure and function 125
 split tolerance 214
 sponges 180
 spores 74

- squamous cell carcinoma 308
 stages of immunity 9
Staphylococcus 6, 16, 21, 157
Staphylococcus aureus 16, 60, 61, 75, 103, 161, 196
 STAT1 202
 STAT4 202
 STAT6 202, 281
 STAT3 signalling 202
 steady state 113, 114, 116, 117, 198
 stem cell factor (SCF) 12, 170, 171
 stem cells 126, 127, 130
 – and gene therapy 130, 131
 – and haematopoiesis 127, 128
 – transplantation 306
 stem cells-haematopoietic-embryonic (ES) 127
 stem cell transplantation 306
 steroids 2, 289, 303
 stomach 6, 99, 101
 stomach acid 81
 stomach (gastric) ulcers 80
 streptavidin 207
Streptococcus 6, 16, 21, 54
Streptococcus pneumoniae 53, 69, 75–77, 96, 110, 157, 235, 241
Streptococcus pyogenes 53, 60, 75
 stromal cells 127, 129
 subcapsular sinus 114, 115
 subclinical infections 39, 40, 50, 56, 103, 250, 252
 subtraction hybridization 193
 subunit vaccines 96
 sulfasalazine 297
 superantigens 196
 superoxide anion (O₂⁻) 159, 160
 suppressor cells 213, 297
 surface plasmon resonance (SPR) 225
 surfactants 101, 102, 154
 swarms 157
 switch regions 245
 Syk 241
 symbiosis 53
 syngeneic 300, 301
 synovium 298, 299
 syphilis 53, 55, 72
 systemic corticosteroids 283
 systemic effects 108
 – of inflammation 11, 166, 168
 systemic immune complexes 288, 289
 – deposition 288
 – SLE animal models 289
 – SLE pathogenesis 289
 systemic infection 81
 systemic inflammatory responses 15, 34, 107
 systemic lupus erythematosus (SLE) 42, 157, 226, 261, 263, 267, 288–290
 – animal models 289
 – concordance for 289
 – pathogenesis 289, 290
 systemic symptoms 75, 82, 84
- t**
 tacrolimus 195, 303, 304
 tapasin 184, 186
 tapeworms 6
 TAP transporters 179, 184, 186
 target cells 182
 tattoos 15
 T-bet transcription factor 66, 199, 202, 282
 T cell–B cell collaboration 123, 196, 243–245
 T cell receptors (TCRs) 7, 9, 25, 26, 28–31, 38, 117, 175, 191, 193, 194, 217, 269, 277
 – activation, roles 193
 – with CD3 177
 – characterization 193
 – and co-stimulatory molecules 31
 – functions of co-receptors on 30
 – generation 209
 – MHC molecules 176, 194
 – peptide–MHC complexes, interactions 177
 – repertoires 278
 – signalling 309
 – structure, and function of 30, 31
 – TCR α 28, 84
 – TCR genes 30, 209, 220
 – transgenic CD4 T cells 214
 T cells 3, 7, 8, 11, 12, 14, 21, 34, 52, 108, 117, 129, 307
 – $\alpha\beta$ T cells 20, 29, 32, 33, 175
 – conventional, subsets of 20
 – thymic selection 212
 – activated T cells 112, 119, 122, 284
 – fates of 119
 – activated cytotoxic CD8 T cells (CTLs) 81
 – activation and polarization 196
 – activation, intracellular signalling 194, 195
 – adoptive transfer, analysis 178
 – alpha chains 29, 32
 – antigen-presenting cells (APCs) 182
 – antigens recognition 175
 – areas 114, 118
 – CD28 cells 192
 – CD80 cells 192
 – CD86 cells 192
 – CD3 populations 177
 – CD4 T cell 30, 32, 77, 78, 82, 90, 176, 205
 – activation 274
 – differentiation 120, 198, 200
 – follicular helper (T_{fh}) T cells 237
 – helper cells 19–21
 – polarization 204
 – populations 176, 177
 – CD8 T cell 176, 178, 182, 205, 206, 302, 304
 – cytotoxic cells 183–185, 203, 216
 – memory 87
 – populations 176, 177
 – central memory cells 122, 208
 – cytotoxic, intracellular proteins 184
 – DC. *See* dendritic cells
 – development and selection 209–215
 – effector functions 214
 – effector memory 122, 208
 – epitopes 30, 271, 272
 – functions 178, 214
 – $\gamma\delta$ T cells 175, 176, 182, 189, 208
 – generation 212, 213
 – $\gamma\delta$ TCRs 212
 – help 39, 202
 – hybridomas 193
 – immunity against infection 178
 – independent responses 125
 – induced regulatory 213
 – in infection, effector and memory functions 196–208
 – lymphoid tissues and 215
 – lymphopenia 293
 – mediated immunity 175, 269
 – in defence and disease 269
 – against infection 177, 178
 – memory 21, 205–208
 – naïve T cells 298
 – CD4 T cell differentiation, influences on 120
 – natural regulatory 213
 – oral and nasal tolerance 214, 215
 – polarization 118
 – populations 175, 176
 – effector functions of 177, 178
 – precursors 12, 176
 – recognition of antigens 116, 175
 – recruitment and activation 121
 – regulatory 213, 214
 – responses in lymph nodes 116
 – secreting cytokines 228
 – $\gamma\delta$ T cells 208, 209
 – types of 20
 – vaccines 215
 T cell signalling 195
 – glucocorticoids, immunosuppressive agents 195, 196
 – immunodeficiencies 195
 – microbial evasion strategies 196
 TCR–CD3 complex 31
 T-dependent (TD) antibody response 21, 75, 121, 124, 218, 236, 237, 243–250
 – affinity maturation 248–250
 – cytokine synthesis, and TLR expression by B cells 244, 245
 – differentiation of activated B cells 245
 – immune responses regulation by Fc receptors 248
 – isotype switching 245–247
 – molecular events in 243, 244
 – primary and secondary antibody responses 243
 – secondary 75
 – T cell–B cell collaboration in 244, 245
 T-dependent B cell activation 238
 – cellular interactions in 238
 terminal deoxynucleotidyl transferase (TdT) 210, 211, 223
 tertiary lymphoid tissues 126, 130, 297
 tetanus 21, 53, 73–75, 95, 231
 – immunization 74
 – pathogenesis and immunity in 74
 – toxin 75
 – toxoid 95
 T_h cells 199, 239
 TGF- β 28, 68, 198–201, 213–215, 228, 247, 278, 280, 309
 T_h3 cells 213, 214
 therapeutic antibodies 44–47, 230, 254–256, 261, 262
 – antibody engineering 254–256
 therapeutic vaccination 44, 45, 94, 309
 thoracic duct 10, 116
 – lymphocytes 116
 thrombocytopenia 286
 thrombus 302
 thrush 6, 53, 91
 T_h0 T cells
 – CD4 T cells 199
 – T_h0 118, 198
 T_h1 T cells

- secrete proinflammatory cytokines 244
- T_h1 20, 21, 32, 34, 65, 66, 78, 118, 198, 199, 201, 202, 204, 227, 244, 248, 264, 268, 276
- CD4 T cells 66, 202
- T_h1-biased CD4 T cells 269
- T_h1 T helper cells 62
- T_h2 T cells
- T_h2 20, 21, 32, 34, 64–67, 118, 145, 198–200, 202, 204, 227, 228, 229, 244, 263, 264, 266, 279, 282
- CD4 T cells 67, 203
- polarization 276
- T_h2-biased CD4 T cells 280
- T_h2-biased responses B cells 229
- T_h2-biased T cells 69, 269
- T_h2-related genes 281
- T_h17 T cells
- T_h17 20, 21, 65, 66, 118, 198, 199, 201, 202, 268, 276, 281, 282
- CD4 T cells 67, 204
- thymic DCs 209
- thymic selection 212
- thymocytes 129, 209, 210
- thymus 11, 12, 38, 68, 127–130, 209, 213, 214
 - cortical epithelial cells (CECs) 129, 210, 212
 - ectopic expression 211
- Thy-1 protein (CD90) 178, 218
- thyroid 285, 302
- thyroid autoimmune diseases 285, 286
 - pathogenesis 285
- thyroid hormones 284, 299
- thyroid-stimulating hormone (TSH)
 - receptor 285
- TI-2 antibody responses 237
- TI-1 antigens 239, 240
- TI-2 antigens 240, 241
- ticks 64
- tight junctions 106, 152
- timothy grass 283
- T-independent (TI) responses 21, 76, 218
- Tinea fungi* 91
- tingible body macrophages 238
- TIP DCs 198
- TI pneumococcal capsular polysaccharide antigens 250
- TIR domain 137, 138
- tissue damage 39, 40, 134, 262
 - mechanisms 262–268
- tissue distribution of antibodies 227
- tissue remodelling 162, 280, 282
- tissue repair 64
- tissue-resident cells 145
 - of innate immunity 147
- tissue-resident macrophages 16
- tissue tropism 207
- TLR1 136
- TLR2 136, 169, 280
- TLR3 137, 138
- TLR4 80, 139, 169, 239, 240, 280
- TLR5 136
- TLR6 136, 169
- TLR7/8 137
- TLR9 96, 137, 239
- TLR11 136
- TLR4 signalling 80
- T lymphocyte activation 191
 - anatomical basis of 191
 - molecular anatomy 192–196
 - molecular requirements for 191, 192
- T lymphocytes (CTLs) 119
- TNF- α 35, 80, 105, 106, 108, 130, 144, 148, 165, 167, 169, 198, 205, 206, 244, 281, 289, 298
- TNF–TNF receptor family 35, 141
- tolerance 31, 37, 38, 113, 118, 192, 198, 261
 - antigen 31, 192, 261
 - B cells 253, 254
 - mechanisms 255, 287
 - cellular proteins 307
 - central/peripheral tolerance 41, 211, 270
 - central tolerance 38, 211, 271
 - process 271
 - DCs 214
 - immunological 37–39, 41, 217, 307
 - mechanisms of induction 39
 - induction, mechanisms of 39
 - mechanisms 198, 255
 - mucosal 283
 - nasal 214, 215
 - oral 200, 214, 215, 283
 - peripheral 38, 66, 213–215
 - self-tolerance 214
 - T cell 287
- toll-like receptors (TLRs) 27, 65, 80, 134, 136, 138, 140–142, 152, 169, 198, 272
 - agonists 141
 - consequences of defects in signalling 138
 - expression 244
 - investigating, signalling via 139
 - role in lipopolysaccharide responsiveness 136
 - signalling pathways 138, 140
 - structure and function 137, 138
 - western blotting 140
- tonsils 11, 111
- toxin 73, 74
 - endotoxins 72
 - neutralization 231, 234
- toxoid 74
- toxoplasma 157
- Toxoplasma gondii* 53, 136
- toxoplasmosis 53
- TRAIL (TNF-related apoptosis-inducing ligand) 90
- transcobalamin II 160
- transcription factors 38, 139, 170, 200, 242
 - AIRE 211
- transendothelial migration 24
- transfection 57
- transforming growth factor (TGF)- β 109, 145, 228, 278
- transfusion reactions 261
- transgenesis 127
- transgenic 296
- transgenic mice 52, 196, 255, 256
- transgenic T cells 119
- transitional B cells 12, 253
- transmigration 26, 106
- transmission 51
- transplant rejections 254, 300–305
 - acute allograft rejection 302–305
 - hyperacute rejection 301, 302
- transplantation 301, 310, 312. *See also* transplant rejections
 - challenge of 2, 3
 - reactions 261
 - terminology 301
- transplantation antigens 43, 261, 300
- transplantation immunology 279, 300–306
 - bone marrow, and stem cell transplantation 306
 - foetus as allograft 306
 - graft-versus-host disease (GVHD) 306
 - graft versus leukaemia effect 306
 - immune responses to transplants 300
 - language of transplantation 300
 - minor histocompatibility antigens 300
 - transplantation reactions, acute rejection 43
 - transplant rejection 300–305
 - acute allograft rejection 302–305
 - hyperacute rejection 301, 302
- trauma 104
- treatment
 - of acute rejection 304
 - of allergy 283
 - of diabetes 293
 - of type II sensitivities 287
- T_{reg} cells 20, 21, 65, 262, 278, 293, 297, 298, 305, 309
- Treponema pallidum* 53, 72, 73
- Trichinella spiralis* 53
- trichinosis 53
- Trichuris suis* 276
- TRIF 138–140
- triple response 147
- trophoblast 306
- tropism 52
- Trypanosoma* 53
- tsetse flies 53
- TSH receptor 286
- T suppressor cells 297
- tuberculosis 6, 11, 16, 21, 54, 63, 65, 73, 78, 97, 144, 178, 207, 256, 297
- tuberculosis, pathogenesis 78
- tumour necrosis factor (TNF)- α 21, 80, 105, 129, 144, 195, 244
- tumours 18, 44, 45, 88, 89, 275
 - evasion of immune responses by 44, 45, 91, 309
 - stages in tumour immunity 310
 - suppressor genes 89
 - tumour antigens 44, 261, 307, 308
 - tumour immune escape mechanisms 311
 - tumour immunity 261, 306–310
 - and Darwin 308
 - immune response by tumours, evasion 309
 - immunotherapy, for cancer 309, 310
 - immunotherapy, goals of 309
 - stages in 309
 - tumour antigenicity 307, 308
 - tumour immunosurveillance 261, 308, 312
- TUNEL (terminal deoxynucleotidyl transferase dUTP nick end-labelling) assay 151
- two-colour flow cytometry 153
- type I, allergic hypersensitivity 263
- type I (insulin-dependent) diabetes 276, 278, 292, 293
- type I hypersensitivity reactions 266
- type II, cytotoxic hypersensitivity 265, 283
- type II (γ) IFN 34
- type III, immune complex-mediated hypersensitivity 263, 268, 288
- type III secretory systems 79
- type I interferons (IFNs) 34, 81, 82, 84, 86, 117, 136, 138, 140, 143, 164, 166, 198

- type II sensitivities, treatment of 287, 288
 type IV, delayed-type hypersensitivity (DTH) 79, 263, 267, 269, 302
 type 3 secretory system 79
 typhoid fever 53, 55, 80, 97
 Typhoid Mary 55
 tyrosine kinase (Lck) 36, 38, 177, 193
 tyrosine phosphatases 36
- u**
- ubiquitin 184, 186
 ulcerative colitis 277, 296
 upper respiratory tract infections 246
 uric acid 141, 172, 275
 urinary tract epithelial cells 146
 urogenital tracts 6, 11, 100, 101, 227
 US Food and Drug Administration, monoclonal antibodies licensed by 254
 uterine cervix carcinoma 88
 uterus 166
- v**
- vaccines 3, 44–46, 75, 83, 88, 89, 93–97, 171, 173, 198, 241, 245, 261
 – design 49
 – live attenuated vaccine 83
 vaccinia virus 66, 95, 178
 vagina 103
 variable and constant regions 28
 variable lymphocyte receptors (VLRs) 224
 variable (V) region 28, 218, 221
 variolation 44, 95
 vascular addressins 24, 106
 vascular smooth muscle 279
 vasodilatation 75, 80, 264
 V, D and J segments 28, 30
 vectors 50, 51, 55
 venom 283
 – factor 238
 venous dilatation 281
 venular vasodilatation 63
 venules 10, 25, 105, 106
Vibrio cholerae 53, 73, 74
 viraemia 92
 viral infections 68, 81, 82, 178
 – initial resistance 81
 – pathogenesis of 81, 92
 –– acute inflammation 84–86
 –– chronic inflammation 86–88
 –– direct cell death 81–84
 –– immunosuppression 90–92
 –– tumours 88–90
 viral RNA 83
 viral tropism 52, 187
 virulence factors 50
 virulent organisms, infection with 95
 viruses 5, 6, 14, 18, 21, 40, 50, 51, 53, 62, 65, 68, 187, 307, 308
 – causing
 –– acute inflammation 84
 –– chronic inflammation 86
 –– immunosuppression 90–92
 –– tumours 88–90
 – epidemics and pandemics 85
 – evasion mechanisms 90–92
 – immunity to polio virus infection 83
 – infection, and viral replication 84
 – life cycles 52
 – recovery, from primary infection 84
 – resistance to re-infection 85
 – symptomatology of infections 84
- vitiligo 308
 vomiting 79
 V region 209, 220
- w**
- warts 88
 WASP 195
 Western blotting 139, 140
 white blood cells 10
 whooping cough 73
 Wiskott–Aldrich syndrome protein (WASP) 194
 worms 14, 21, 53, 64, 66
 wound 109
- x**
- X chromosome 252
 xenogeneic 301
 xenografts 43, 274, 300, 301
 X-linked defect 162
 X-ray crystallography 180, 188, 218, 221
- y**
- yeast 91
 – and fungal infections, pathogenesis of 91, 92
 yellow fever 59, 97, 232
Yersinia pestis 53
- z**
- ZAP70 194, 195
 ZIP code 59, 106, 149
 – principle 25, 26, 151, 152
 zoonoses 59

